Renyan Liu
Renyan Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Caoibhne McSweeney
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
12 shared publications - Constantia Pantelidou
Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, USA
12 shared publications - Daryl Griffin
Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
12 shared publications - Geoffrey I. Shapiro
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
12 shared publications - Heta Jadhav
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
12 shared publications - Jie Hao
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
12 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
BET inhibition induces apoptosis, cell cycle arrest, and senescence in palbociclib-resistant cells.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
BET inhibition induces apoptosis, cell cycle arrest, and senescence in palbociclib-resistant cells.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
MiRNA associated with the top three differential KEGG pathway signatures identified by RNA-seq in response to short-term JQ1 treatment.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
MiRNA associated with the top three differential KEGG pathway signatures identified by RNA-seq in response to short-term JQ1 treatment.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Synergy analyses of the effects of the combination of palbociclib and JQ1.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Synergy analyses of the effects of the combination of palbociclib and JQ1.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
RNA-seq analysis in vehicle and JQ1-treated palbociclib-resistant MCF7-R100 cells.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
RNA-seq analysis in vehicle and JQ1-treated palbociclib-resistant MCF7-R100 cells.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
BET inhibition reverses palbociclib resistance.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
BET inhibition reverses palbociclib resistance.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Preclinical efficacy and toxicity studies of JQ1 and palbociclib.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Preclinical efficacy and toxicity studies of JQ1 and palbociclib.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Identification of miR-34a-5p but not miR-34a-3p as a key miRNA mediating the effect of JQ1 on palbociclib-resistant cells.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Identification of miR-34a-5p but not miR-34a-3p as a key miRNA mediating the effect of JQ1 on palbociclib-resistant cells.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Palbociclib downregulates BCL-2 and sensitizes cells to JQ1.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Palbociclib downregulates BCL-2 and sensitizes cells to JQ1.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Data from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Purpose:CDK6 overexpression is one critical determinant of acquired CDK4/6 inhibitor resistance. Because BRD4 is recruited to the CDK6 promoter, we investigated the potential of bromodomain and extraterminal domain (BET) inhibition to reverse CDK4/6 inhibitor resistance.Experimental Design:Cell viability and survival assays and cell line xenografts were used to evaluate BET inhibition in palbociclib-resistant breast cancer cells. Vehicle- and BET inhibitor–treated cells were subjected to RNA sequencing. CDK6 promoter activity was assessed with luciferase assays, and the miRPathDB version 2.0 database was used to identify potential miRNA mediating the effects of BET inhibition. Experiments were conducted to determine whether continued palbociclib treatment is essential for BET inhibitor efficacy and to explore associated mechanisms.Results:In CDK4/6 inhibitor–resistant models overexpressing CDK6, a cell-cycle gene signature was differentially downregulated following BET inhibition. The BET inhibitors JQ1 and ZEN-3694 reduced the expression of CDK6 and cyclin D1, reinstated CDK4/6 inhibitor–induced cell-cycle arrest, and triggered apoptosis in vitro, as well as tumor regression in vivo. Mechanistically, BET inhibition downregulated CDK6 expression through the induction of miR-34a-5p, rather than by directly repressing the CDK6 promoter. Introduction of a miR-34a-5p inhibitor abrogated BET inhibitor–mediated molecular changes, whereas a miR-34a-5p mimic replicated the effects of BET inhibition. Lastly, resistant cells exhibited downregulation of BCL-2 in the presence of continued palbociclib, associated with reduced estrogen receptor alpha expression, facilitating sensitivity to BET inhibition.Conclusions:Our findings highlight BET inhibition or the application of miR-34a-5p mimics as promising strategies to reverse CDK4/6 inhibitor resistance in a subset of ER+ breast cancers.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p
Purpose:CDK6 overexpression is one critical determinant of acquired CDK4/6 inhibitor resistance. Because BRD4 is recruited to the CDK6 promoter, we investigated the potential of bromodomain and extraterminal domain (BET) inhibition to reverse CDK4/6 inhibitor resistance.Experimental Design:Cell viability and survival assays and cell line xenografts were used to evaluate BET inhibition in palbociclib-resistant breast cancer cells. Vehicle- and BET inhibitor–treated cells were subjected to RNA sequencing. CDK6 promoter activity was assessed with luciferase assays, and the miRPathDB version 2.0 database was used to identify potential miRNA mediating the effects of BET inhibition. Experiments were conducted to determine whether continued palbociclib treatment is essential for BET inhibitor efficacy and to explore associated mechanisms.Results:In CDK4/6 inhibitor–resistant models overexpressing CDK6, a cell-cycle gene signature was differentially downregulated following BET inhibition. The BET inhibitors JQ1 and ZEN-3694 reduced the expression of CDK6 and cyclin D1, reinstated CDK4/6 inhibitor–induced cell-cycle arrest, and triggered apoptosis in vitro, as well as tumor regression in vivo. Mechanistically, BET inhibition downregulated CDK6 expression through the induction of miR-34a-5p, rather than by directly repressing the CDK6 promoter. Introduction of a miR-34a-5p inhibitor abrogated BET inhibitor–mediated molecular changes, whereas a miR-34a-5p mimic replicated the effects of BET inhibition. Lastly, resistant cells exhibited downregulation of BCL-2 in the presence of continued palbociclib, associated with reduced estrogen receptor alpha expression, facilitating sensitivity to BET inhibition.Conclusions:Our findings highlight BET inhibition or the application of miR-34a-5p mimics as promising strategies to reverse CDK4/6 inhibitor resistance in a subset of ER+ breast cancers.